臨床試驗
Clinical trial results have shown that Cladribine tablets can be an effective treatment for highly active relapsing forms of MS, with significant clinical benefits in relapse rate, disability progression and radiological measures. Compared with placebo, patients who received Cladribine tablets (3.5 mg/kg) in the CLARITY study had a 58% reduction in annualized relapse rate and 47% of patients showed no evidence of disease activity at 2 years. Clinical improvements can be observed at Week 24 of treatment, and benefits may be sustained up to 4 years, beyond the 2-year dosing period and recovery of total lymphocytes. "Post-hoc" analyses of clinical trial data showed that 89% of patients remained free from disability progression two years after treatment.